TGF beta Receptor III antibody

Cat No. GTX10854

Host	Goat
Clonality	Polyclonal
Isotype	IgG
Application	WB, ELISA
Reactivity	Human

See all TGF beta Receptor III products

Datasheet

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Application	Dilution
WB	1-2 μg/ml
ELISA	0.5-1 μg/ml

Not tested in other applications.

Calculated MW

94 kDa. ( Note )

PROPERTIES

Form

Liquid

Buffer

PBS containing carbohydrates

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Antigen Species

Human

Immunogen

recombinant human TGF-β sRIII (betaglycan) expressed in NSO cells

Purification

Purified by affinity chromatography

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

TARGET

Synonyms

Transforming Growth Factor Beta Receptor 3,Bgcan,Betaglycan,Tgfbr3

Background

Most mammalian cells express three abundant high affinity receptors, which can bind and be cross-linked to TGF beta: the type I (53 kDa), type II (65 kDa), and type III (100-280 kDa) receptors, based upon the molecular mass of the cross-linked products analyzed by gel electrophoresis. Tbeta-RI and Tbeta-RII, the type I and II receptors, are type I transmembrane proteins with cytosolic domains containing a serine-threonine kinase. Both receptors are essential for signal transduction. The TGF beta type III receptor, or betaglycan, is a membrane-bound proteoglycan with a short cytoplasmic tail that has no apparent signaling motif. It binds TGF beta 2 (apparent Kd 100 pM) with slightly greater affinity than TGF beta 1 or TGF beta 3 (apparent Kda 300 pM). The main role of betaglycan seems to be in binding and then presenting TGF beta ligand to the signaling receptors Tbeta-RI and Tbeta-RII; overexpression of Tbeta-RIII in L6 myoblasts leads to a dramatic increase in TGF beta 2 binding to Tbeta-RI and Tbeta-RII.